| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 IARC, Lyon, France; Departments of 2 Environmental Medicine and 3 Obstetrics and Gynecology, New York University School of Medicine, New York, New York; 4 Department of Urology and Andrology, Umeå University Hospital, Umeå, Sweden
Requests for reprints: Rudolf Kaaks, Nutrition and Hormones Group, IARC, 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France. Phone: 347-273-8553; Fax: 347-273-8361. E-mail: kaaks{at}iarc.fr
Circulating insulin-like growth factor-I (IGF-I) and its major binding protein IGF binding protein-3 (IGFBP-3) have been associated with increased risk of premenopausal breast cancer, although risk estimates varied broadly. An extension of a case-control study (138 cases, 259 matched controls) on IGF-I and breast cancer in premenopausal women nested in the New York University Women's Health Study cohort offered the opportunity to address the hypothesis that such variability may have been the result of variations in the ability of different IGFBP-3 assays to specifically measure intact/functional forms of the protein. IGF-I and IGFBP-3 had originally been measured using in-house RIAs. These measurements were repeated using commercially available ELISAs [Diagnostic System Laboratories (DSL), Webster, Texas], and a third ELISA with greater specificity for active forms for IGFBP-3. Pearson's correlations between IGF-I concentrations in the original study and DSL ELISA were very high [r = 0.92; 95% CI, 0.90-0.94]. Correlations with DSL ELISA were much lower for IGFBP-3 (r = 0.58; 0.49-0.66) and even lower still with the assay for functional IGFBP-3 (r = 0.33; 0.20-0.44). IGF-I and IGFBP-3 measurements by the DSL ELISA methods showed statistically significant relationships with risk. The odds ratios (OR) for top versus bottom quartiles were 1.93 (1.00-3.72; P = 0.02) and 2.03 (1.09-3.76; P = 0.02), respectively, in agreement with the original observations. In contrast, measurements of functional IGFBP-3 tended to be unrelated to risk [ORs for the top versus bottom quartile, 0.97 (0.44-2.11)]. The association with IGF-I became substantially weaker and lost statistical significance after adjustment for IGFBP-3 using DSL ELISA, but became considerably stronger when adjusting for the functional IGFBP-3 measurements [OR = 2.43 (1.21-4.90); P = 0.005], or when considering the molar ratio of IGF-I to IGFBP-3 [OR = 2.37 (1.13-5.00); P = 0.02]. These results are consistent with an association of breast cancer risk in young women with elevated IGF-I and IGFBP-3, and show that for IGFBP-3, the strength of such an association could vary substantially depending on the assay used.
Key Words: Premenopausal breast cancer • IGF-I • IGFBP-3 • Cohort studies • assay methods
This article has been cited by other articles:
|
|
 |
|
  V. M. Chia, S. M. Quraishi, B. I. Graubard, M. V. Rubertone, R. L. Erickson, F. Z. Stanczyk, and K. A. McGlynn Insulin-like Growth Factor 1, Insulin-like Growth Factor-Binding Protein 3, and Testicular Germ-Cell Tumor Risk Am. J. Epidemiol., June 15, 2008; 167(12): 1438 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Siahpush, T. L. Vaughan, J. N. Lampe, R. Freeman, S. Lewis, R. D. Odze, P. L. Blount, K. Ayub, P. S. Rabinovitch, B. J. Reid, et al. Longitudinal Study of Insulin-like Growth Factor, Insulin-like Growth Factor Binding Protein-3, and their Polymorphisms: Risk of Neoplastic Progression in Barrett's Esophagus Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2387 - 2395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sieri, V. Pala, F. Brighenti, N. Pellegrini, P. Muti, A. Micheli, A. Evangelista, S. Grioni, P. Contiero, F. Berrino, et al. Dietary glycemic index, glycemic load, and the risk of breast cancer in an Italian prospective cohort study Am. J. Clinical Nutrition, October 1, 2007; 86(4): 1160 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S Schernhammer, S. S Tworoger, A H. Eliassen, S. A Missmer, J. M Holly, M. N Pollak, and S. E Hankinson Body shape throughout life and correlations with IGFs and GH Endocr. Relat. Cancer, September 1, 2007; 14(3): 721 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. E. Allen, T. J. Key, P. N. Appleby, R. C. Travis, A. W. Roddam, S. Rinaldi, L. Egevad, S. Rohrmann, J. Linseisen, T. Pischon, et al. Serum Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3 Concentrations and Prostate Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1121 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Berrigan, N. Potischman, K. W. Dodd, M. Nicar, G. McQuillan, J. A. Lavigne, J. C. Barrett, and R. Ballard-Barbash Serum Levels of Insulin-like Growth Factor-I and Insulin-like Growth Factor-I Binding Protein-3: Quality Control for Studies of Stored Serum Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 1017 - 1022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Baglietto, D. R. English, J. L. Hopper, H. A. Morris, W. D. Tilley, and G. G. Giles Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and the Risk of Breast Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 763 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Pazaitou-Panayiotou, T. Kelesidis, I. Kelesidis, A. Kaprara, J. Blakeman, I. Vainas, A. Mpousoulegas, C. J Williams, and C. Mantzoros Growth hormone-binding protein is directly and IGFBP-3 is inversely associated with risk of female breast cancer Eur. J. Endocrinol., February 1, 2007; 156(2): 187 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G Renehan, M. Harvie, and A. Howell Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr. Relat. Cancer, June 1, 2006; 13(2): 273 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S Schernhammer, J. M Holly, D. J Hunter, M. N Pollak, and S. E Hankinson Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr. Relat. Cancer, June 1, 2006; 13(2): 583 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Rinaldi, P H M Peeters, F Berrino, L Dossus, C Biessy, A Olsen, A Tjonneland, K Overvad, F Clavel-Chapelon, M C Boutron-Ruault, et al. IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr. Relat. Cancer, June 1, 2006; 13(2): 593 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. dos Santos Silva, N. Johnson, B. De Stavola, G. Torres-Mejia, O. Fletcher, D. S. Allen, N. E. Allen, T. J. Key, I. S. Fentiman, J. M.P. Holly, et al. The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 449 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Al-Zahrani, M. S. Sandhu, R. N. Luben, D. Thompson, C. Baynes, K. A. Pooley, C. Luccarini, H. Munday, B. Perkins, P. Smith, et al. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer Hum. Mol. Genet., January 1, 2006; 15(1): 1 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Renehan Insulin-Like Growth Factor-Binding Protein-3, Breast Cancer Risk, and Different Serum Assays Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1844 - 1844. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
